The Changing Insulin Affordability Landscape: Lower Out-of-Pocket Costs and Expanded Access Pathways

KEY POINTS

• Average out-of-pocket spending for insulin has declined across commercial insurance, Medicare, and cash/assistance channels in recent years.
• Competition among manufacturers and retailers, combined with consumer-empowerment tools such as TrumpRx, has substantially improved insulin affordability.
• Across every major payer category—Medicare, Medicaid, private insurance, and the uninsured—multiple pathways exist to access insulin products at or below $35 per month.

*This content is in the process of Section 508 review. If you need immediate assistance accessing this content, please submit a request to Stephen Murphy, Stephen.Murphy@hhs.gov. Content will be updated pending the outcome of the Section 508 review.